To investigate the safety and pharmacokinetic profile of ascending doses of desvenlafaxine in children and adolescents with major depressive disorder. Assessment of the effect of desvenlafaxine on depression symptoms was exploratory.
Methods:
The 8-week, open-label study included an initial 3.5-day inpatient period followed by a 7.5-week outpatient period. Children (7–11 years) received a single desvenlafaxine dose of 10, 25, 50, or 100 mg on day 1; adolescents (12–17 years) received desvenlafaxine 25, 50, 100, or 200 mg/day. Plasma and urine samples were collected over the initial 72-hour inpatient period. Evaluations included treatment-emergent adverse events (TEAEs), physical examinations (including Tanner Staging), vital signs, laboratory assessments, 12-lead electrocardiogram, Columbia-Suicide Severity Rating Scale, and the Children's Depression Rating Scale-Revised (CDRS-R).
Results:
In all, 29 children and 30 adolescents took at least one dose of desvenlafaxine and were included in the safety population (children: 10 mg, n = 6; 25 mg, n = 7; 50 mg, n = 9; 100 mg, n = 7; adolescents: 25 mg, n = 7; 50 mg, n = 7; 100 mg, n = 8; 200 mg, n = 8). Total area under the drug concentration-time curve from 0 to infinity (AUC) appeared to increase linearly with increasing dose. Mean (standard deviation [SD]) AUC ranged from 628 (346) ng/mL (desvenlafaxine 10 mg) to 6732 (3031) ng/mL (100 mg) in children and from 1123 (361) ng/mL (25 mg) to 11,730 (3113) ng/mL (200 mg) in adolescents. During the combined inpatient and outpatient period, 16/29 (55%) children and 21/30 (70%) adolescents reported at least one TEAE. One serious adverse event (suicidal behavior) was reported. Mean (SD) change from baseline in CDRS-R total scores at week 8 was −19.00 (9.87) for children and −21.57 (11.50) for adolescents.
Conclusions:
Desvenlafaxine AUC values increased linearly with dose; body weight alone provided an adequate prediction for dose-normalized AUC. Desvenlafaxine was generally safe and well tolerated in children and adolescents for treatment up to 8 weeks.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision [DSM-IV-TR], Washington, DC: American Psychiatric Association; 2000.
2.
AtkinsonSD, PrakashA, ZhangQ, PangalloBA, BangsME, EmslieGJ, MarchJS: A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 24:180–189, 2014.
3.
AvenevoliS, SwendsenJ, HeJP, BursteinM, MerikangasKR: Major depression in the national comorbidity survey-adolescent supplement: Prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry, 54:37–44, 2015.
4.
Baird-BellaireS, BehrleJA, ParkerVD, PatatA, PaulJ, NicholsAI: An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther, 35:782–794, 2013.
5.
BirmaherB, BrentD, BernetW, BuksteinO, WalterH, BensonRS, ChrismanA, FarchioneT, GreenhillL, HamiltonJ, KeableH, KinlanJ, SchoettleU, StockS, PtakowskiKK, MedicusJ: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry, 46:1503–1526, 2007.
6.
BirmaherB, RyanND, WilliamsonDE, BrentDA, KaufmanJ, DahlRE, PerelJ, NelsonB: Childhood and adolescent depression: A review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry, 35:1427–1439, 1996.
7.
BliznakL, BergR, HageA, DittmannRW: High rate of non-eligibility: Methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder. Pharmacopsychiatry, 46:23–28, 2013.
8.
BridgeJA, BirmaherB, IyengarS, BarbeRP, BrentDA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry, 166:42–49, 2009.
9.
BridgeJA, IyengarS, SalaryCB, BarbeRP, BirmaherB, PincusHA, RenL, BrentDA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA, 297:1683–1696, 2007.
10.
CheungAH, EmslieGJ, MayesTL: The use of antidepressants to treat depression in children and adolescents. CMAJ, 174:193–200, 2006.
11.
CheungAH, ZuckerbrotRA, JensenPS, GhalibK, LaraqueD, SteinRE: Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics, 120:e1313–e1326, 2007.
12.
ClaytonAH, KornsteinSG, RosasG, Guico-PabiaC, TourianKA: An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr, 14:183–195, 2009.
13.
ClinicalTrials.gov. A study of DVS SR in treatment of children and adolescent outpatients with MDD NCT01371734. Updated September8, 2014a. Available at http://clinicaltrials.gov/show/NCT01371734. Accessed October2, 2014.
14.
ClinicalTrials.gov. A study of DVS SR in treatment of children and adolescent outpatients with MDD NCT01372150. Updated September8, 2014b. Available at http://clinicaltrials.gov/show/NCT01372150. Accessed October2, 2014.
15.
Cymbalta [package insert], Indianapolis, IN: Eli Lilly and Company; 2015.
EdwardsAC, JoinsonC, DickDM, KendlerKS, MacleodJ, MunafoM, HickmanM, LewisG, HeronJ: The association between depressive symptoms from early to late adolescence and later use and harmful use of alcohol. Eur Child Adolesc Psychiatry, 23:1219–1230, 2014.
EmslieG, KratochvilC, VitielloB, SilvaS, MayesT, McnultyS, WellerE, WaslickB, CasatC, WalkupJ, PathakS, RohdeP, PosnerK, MarchJ: Treatment for adolescents with depression study (TADS): Safety results. J Am Acad Child Adolesc Psychiatry, 45:1440–1455, 2006.
20.
EmslieGJ, FindlingRL, YeungPP, KunzNR, LiY: Venlafaxine ER for the treatment of pediatric subjects with depression: Results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry, 46:479–488, 2007.
21.
EmslieGJ, PrakashA, ZhangQ, PangalloBA, BangsME, MarchJS: A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 24:170–179, 2014.
22.
FeighnerJP: Cardiovascular safety in depressed patients: Focus on venlafaxine. J Clin Psychiatry, 56:574–579, 1995.
23.
Fetzima [package insert], St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014.
24.
FindlingRL, GroarkJ, ChilesD, RamakerS, YangL, TourianKA: Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 24:201–209, 2014.
25.
FindlingRL, McnamaraNK, StansbreyRJ, FeenyNC, YoungCM, PericFV, YoungstromEA: The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol, 16:131–145, 2006.
26.
Food and Drug Administration (FDA): Don't leave childhood depression untreated. Updated September2014. Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm413161.htm. Accessed March24, 2015.
27.
GuyW: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976, pp. 217–222.
28.
HamiltonM: A rating scale for depression. J Neurol Neurosurg Psychiatry, 23:56–62, 1960.
29.
International Conference on Harmonisation: ICH harmonised tripartite guideline: Statistical principles for clinical trials E9. Updated February5, 1998. Available at http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/statistical-principles-for-clinical-trials.html. Accessed April30, 2012.
30.
KaufmanJ, BirmaherB, BrentD, RaoU, FlynnC, MoreciP, WilliamsonD, RyanN: Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36:980–988, 1997.
31.
KuczmarskiRJ, OgdenCL, GuoSS, Grummer-StrawnLM, FlegalKM, MeiZ, WeiR, CurtinLR, RocheAF, JohnsonCL: 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat, 11:1–190, 2002.
32.
Lexapro [package insert], St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014.
33.
MaD, ZhangZ, ZhangX, LiL: Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: A multiple-treatments meta-analysis. Curr Med Res Opin, 30:971–995, 2014.
34.
MarchJ, SilvaS, PetryckiS, CurryJ, WellsK, FairbankJ, BurnsB, DominoM, McnultyS, VitielloB, SevereJ: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292:807–820, 2004.
35.
MarmorsteinNR: Longitudinal associations between alcohol problems and depressive symptoms: Early adolescence through early adulthood. Alcohol Clin Exp Res, 33:49–59, 2009.
36.
National Collaborating Centre for Mental Health: Depression in children and young people: Identification and management in primary, community and secondary care. Clinical Guideline 28. Updated September2005. Available at http://www.nice.org.uk/CG028. Accessed April19, 2012.
37.
NicholsAI, RichardsLS, BehrleJA, PosenerJA, McgrorySB, PaulJ: The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther, 49:3–13, 2011.
38.
PosnerK, BrownGK, StanleyB, BrentDA, YershovaKV, OquendoMA, CurrierGW, MelvinGA, GreenhillL, ShenS, MannJJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry, 168:1266–1277, 2011.
39.
PoznanskiEO, CookSC, CarrollBJ: A depression rating scale for children. Pediatrics, 64:442–450, 1979.
40.
PreskornSH, NicholsAI, PaulJ, PatronevaAL, HelznerEC, Guico-PabiaCJ: Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract, 14:368–378, 2008.
41.
Pristiq [package insert], Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2015.
42.
Prozac [package insert], Indianapolis, IN: Eli Lilly and Company; 2014.
43.
RottenbergJ, YaroslavskyI, CarneyRM, FreedlandKE, GeorgeCJ, BajiI, DochnalR, GadorosJ, HalasK, KapornaiK, KissE, OsvathV, VargaH, VetroA, KovacsM: The association between major depressive disorder in childhood and risk factors for cardiovascular disease in adolescence. Psychosom Med, 76:122–127, 2014.
44.
Royal Australian College of General Practitioners: Clinical guidance on the use of antidepressant medications in children and adolescents. Updated March2005. Available at http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/Clinicalguidanceontheuseofantidepressantmedicationsinchildrenandadolescents/200709SSRIs_for_children.pdf. Accessed May21, 2012.
45.
SheltonRC: Serotonin norepinephrine reuptake inhibitors: Similarities and differences. Prim Psychiatry, 15:25–35, 2009.
46.
TannerJM: Growth at Adolecence. Oxford, England: Blackwell Scientific Publications, 1962.
47.
ThaseME: Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry, 59:502–508, 1998.
48.
TsapakisEM, SoldaniF, TondoL, BaldessariniRJ: Efficacy of antidepressants in juvenile depression: Meta-analysis. Br J Psychiatry, 193:10–17, 2008.
49.
US Preventive Services Task Force: Screening and treatment for major depressive disorder in children and adolescents: US preventive services task force recommendation statement. Pediatrics, 123:1223–1228, 2009.
50.
WaloszekJM, ByrneML, WoodsMJ, NicholasCL, BeiB, MurrayG, RanitiM, AllenNB, TrinderJ: Early physiological markers of cardiovascular risk in community based adolescents with a depressive disorder. J Affect Disord, 175:403–410, 2015.
51.
World Health Organization: Health for the World's Adolescents. A second chance in the second decade. Executive Summary. Updated 2014. Available at http://apps.who.int/adolescent/second-decade/files/1612_MNCAH_HWA_Executive_Summary.pdf. Accessed March30, 2015.
